Personal information

Other IDs

Loop profile: 1012968

Activities

Collapse all

Employment (1)

Tennessee Oncology: Nashville, US

2025-01-01 to present | Medical Director of Genitourinary Research
Employment
Source: Self-asserted source
Kathryn Beckermann

Works (50 of 60)

Items per page:
Page 1 of 2

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

Clinical Cancer Research
2024-06-03 | Journal article
DOI: 10.1158/1078-0432.CCR-23-3029
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Data from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.c.7265741
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Data from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.c.7265741.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Figure S1 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956254.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Figure S1 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956254
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Figure S2 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956251
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Figure S2 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956251.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Figure S3 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956248.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Figure S3 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956248
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Figure S4 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956245
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Figure S4 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956245.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Figure S5 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956239.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Figure S5 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956239
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Figure S6 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956236.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Figure S6 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956236
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Figure S7 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956233.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Figure S7 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956233
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Methods S1 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956230.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Methods S1 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956230
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Table S1 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956227.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Table S1 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956227
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Table S2 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956224
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Table S2 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956224.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Table S3 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956221.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Table S3 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956221
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Table S4 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956218
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Table S4 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956218.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Table S5 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956215.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Table S5 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956215
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Table S6 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956212
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Table S6 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956212.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Table S7 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956209.v1
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Supplementary Table S7 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956209
Contributors: James Brugarolas; Gregory Obara; Kathryn E. Beckermann; Brian Rini; Elaine T. Lam; James Hamilton; Thomas Schluep; Min Yi; So Wong; Zhongping Lily Mao et al.
Source: check_circle
Crossref

Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

Clinical Cancer Research
2024-05-01 | Journal article
DOI: 10.1158/1078-0432.CCR-23-2592
Contributors: Tobias Else; Eric Jonasch; Othon Iliopoulos; Kathryn E. Beckermann; Vivek Narayan; Benjamin L. Maughan; Stephane Oudard; Jodi K. Maranchie; Ane B. Iversen; Cynthia M. Goldberg et al.
Source: check_circle
Crossref

Data from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024-05-01 | Preprint
DOI: 10.1158/1078-0432.c.7209076.v1
Contributors: Tobias Else; Eric Jonasch; Othon Iliopoulos; Kathryn E. Beckermann; Vivek Narayan; Benjamin L. Maughan; Stephane Oudard; Jodi K. Maranchie; Ane B. Iversen; Cynthia M. Goldberg et al.
Source: check_circle
Crossref

Data from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024-05-01 | Preprint
DOI: 10.1158/1078-0432.c.7209076
Contributors: Tobias Else; Eric Jonasch; Othon Iliopoulos; Kathryn E. Beckermann; Vivek Narayan; Benjamin L. Maughan; Stephane Oudard; Jodi K. Maranchie; Ane B. Iversen; Cynthia M. Goldberg et al.
Source: check_circle
Crossref

Supplementary Figure 1 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024-05-01 | Preprint
DOI: 10.1158/1078-0432.25728553
Contributors: Tobias Else; Eric Jonasch; Othon Iliopoulos; Kathryn E. Beckermann; Vivek Narayan; Benjamin L. Maughan; Stephane Oudard; Jodi K. Maranchie; Ane B. Iversen; Cynthia M. Goldberg et al.
Source: check_circle
Crossref

Supplementary Figure 1 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024-05-01 | Preprint
DOI: 10.1158/1078-0432.25728553.v1
Contributors: Tobias Else; Eric Jonasch; Othon Iliopoulos; Kathryn E. Beckermann; Vivek Narayan; Benjamin L. Maughan; Stephane Oudard; Jodi K. Maranchie; Ane B. Iversen; Cynthia M. Goldberg et al.
Source: check_circle
Crossref

Supplementary Figure 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024-05-01 | Preprint
DOI: 10.1158/1078-0432.25728547.v1
Contributors: Tobias Else; Eric Jonasch; Othon Iliopoulos; Kathryn E. Beckermann; Vivek Narayan; Benjamin L. Maughan; Stephane Oudard; Jodi K. Maranchie; Ane B. Iversen; Cynthia M. Goldberg et al.
Source: check_circle
Crossref

Supplementary Figure 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024-05-01 | Preprint
DOI: 10.1158/1078-0432.25728547
Contributors: Tobias Else; Eric Jonasch; Othon Iliopoulos; Kathryn E. Beckermann; Vivek Narayan; Benjamin L. Maughan; Stephane Oudard; Jodi K. Maranchie; Ane B. Iversen; Cynthia M. Goldberg et al.
Source: check_circle
Crossref

Supplementary Table 1 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024-05-01 | Preprint
DOI: 10.1158/1078-0432.25728544.v1
Contributors: Tobias Else; Eric Jonasch; Othon Iliopoulos; Kathryn E. Beckermann; Vivek Narayan; Benjamin L. Maughan; Stephane Oudard; Jodi K. Maranchie; Ane B. Iversen; Cynthia M. Goldberg et al.
Source: check_circle
Crossref

Supplementary Table 1 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024-05-01 | Preprint
DOI: 10.1158/1078-0432.25728544
Contributors: Tobias Else; Eric Jonasch; Othon Iliopoulos; Kathryn E. Beckermann; Vivek Narayan; Benjamin L. Maughan; Stephane Oudard; Jodi K. Maranchie; Ane B. Iversen; Cynthia M. Goldberg et al.
Source: check_circle
Crossref

Supplementary Table 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024-05-01 | Preprint
DOI: 10.1158/1078-0432.25728541
Contributors: Tobias Else; Eric Jonasch; Othon Iliopoulos; Kathryn E. Beckermann; Vivek Narayan; Benjamin L. Maughan; Stephane Oudard; Jodi K. Maranchie; Ane B. Iversen; Cynthia M. Goldberg et al.
Source: check_circle
Crossref

Supplementary Table 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024-05-01 | Preprint
DOI: 10.1158/1078-0432.25728541.v1
Contributors: Tobias Else; Eric Jonasch; Othon Iliopoulos; Kathryn E. Beckermann; Vivek Narayan; Benjamin L. Maughan; Stephane Oudard; Jodi K. Maranchie; Ane B. Iversen; Cynthia M. Goldberg et al.
Source: check_circle
Crossref

Supplementary Table 3 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024-05-01 | Preprint
DOI: 10.1158/1078-0432.25728538.v1
Contributors: Tobias Else; Eric Jonasch; Othon Iliopoulos; Kathryn E. Beckermann; Vivek Narayan; Benjamin L. Maughan; Stephane Oudard; Jodi K. Maranchie; Ane B. Iversen; Cynthia M. Goldberg et al.
Source: check_circle
Crossref

Supplementary Table 3 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024-05-01 | Preprint
DOI: 10.1158/1078-0432.25728538
Contributors: Tobias Else; Eric Jonasch; Othon Iliopoulos; Kathryn E. Beckermann; Vivek Narayan; Benjamin L. Maughan; Stephane Oudard; Jodi K. Maranchie; Ane B. Iversen; Cynthia M. Goldberg et al.
Source: check_circle
Crossref

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial

The Oncologist
2024-03-04 | Journal article
DOI: 10.1093/oncolo/oyad348
Contributors: Kathryn E Beckermann; Aviva G Asnis-Alibozek; Michael B Atkins; Bernard Escudier; Thomas E Hutson; Vijay Kasturi; David F McDermott; Sumanta K Pal; Camillo Porta; Brian I Rini et al.
Source: check_circle
Crossref

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors

JTO Clinical and Research Reports
2024-02 | Journal article
DOI: 10.1016/j.jtocrr.2023.100619
Contributors: Kathryn E. Beckermann; Christine M. Bestvina; Badi El Osta; Rachel E. Sanborn; Hossein Borghaei; Philip Edward Lammers; Giovanni Selvaggi; Jennifer G. Whisenant; Ellen Heimann-Nichols; Lynne Berry et al.
Source: check_circle
Crossref

Therapies in Refractory Metastatic Renal Cell Carcinoma

Société Internationale d’Urologie Journal
2022-11-16 | Journal article
DOI: 10.48083/KGTQ6832
Contributors: Stephanie Berg; Martin Angel; Kathryn E. Beckermann; Frede Donskov; Chung-Han Lee; Pavlos Msaouel; Rana R. McKay; Tian Zhang
Source: check_circle
Crossref

Emerging Targets in Clear Cell Renal Cell Carcinoma

Cancers
2022-10-04 | Journal article
DOI: 10.3390/cancers14194843
Contributors: Yu-Wei Chen; Brian I. Rini; Kathryn E. Beckermann
Source: check_circle
Crossref
grade
Preferred source (of 2)‎
Items per page:
Page 1 of 2

Peer review (4 reviews for 4 publications/grants)

Review activity for Cell death and disease. (1)
Review activity for Clinical genitourinary cancer. (1)
Review activity for Journal for immunotherapy of cancer. (1)
Review activity for Journal of the National Cancer Institute : (1)
How many people are using ORCID?